Increased hepcidin levels in high-altitude pulmonary edema

Journal of Applied Physiology

Volumn 118, Issue 3, 2015, Pages 292-298

  Altamura, Sandro ^a   Bärtsch, Peter ^a   Dehnert, Christoph ^a   Maggiorini, Marco ^b   Weiss, Günter ^c   Theurl, Igor ^c   Muckenthaler, Martina U ^a   Mairbäurl, Heimo ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Erythropoiesis; Ferritin; Hepcidin; Iron; Pulmonary arterial hypertension; Pulmonary edema

Indexed keywords

CARBOLINE DERIVATIVE; DEXAMETHASONE; HEPCIDIN; INTERLEUKIN 6; IRON; TADALAFIL;

ALTITUDE; ALTITUDE DISEASE; ANOXIA; ARTERIAL PRESSURE; BLOOD; DRUG EFFECTS; HUMAN; LUNG; METABOLISM; PHYSIOLOGY; PULMONARY HYPERTENSION; VASOCONSTRICTION;

ALTITUDE; ALTITUDE SICKNESS; ANOXIA; ARTERIAL PRESSURE; CARBOLINES; DEXAMETHASONE; HEPCIDINS; HUMANS; HYPERTENSION, PULMONARY; INTERLEUKIN-6; IRON; LUNG; TADALAFIL; VASOCONSTRICTION;

EID: 84922339991     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.00940.2014     Document Type: Article

References (30)

1. Bärtsch P. High altitude pulmonary edema. Med Sci Sports Exercise 31: S23-S27, 1999.
2. Bärtsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O. Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med 325: 1284-1289, 1991.
3. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 131: 568S-579S, 2001.
4. Dehnert C, Grunig E, Mereles D, von Lennep N, Bartsch P. Identification of individuals susceptible to high-altitude pulmonary oedema at low altitude. Eur Respir J 25: 545-551, 2005.
5. Dehnert C, Luks AM, Schendler G, Menold E, Berger MM, Mairbäurl H, Faoro V, Bailey DM, Castell C, Hahn G, Vock P, Swenson ER, Bartsch P. No evidence for interstitial lung oedema by extensive pulmonary function testing at 4559 m. Eur Respir J 35: 812-820, 2010.
6. Frazier MD, Mamo LB, Ghio AJ, Turi JL. Hepcidin expression in human airway epithelial cells is regulated by interferon-gamma. Respir Res 12: 100, 2011.
7. Goetze O, Schmitt J, Spliethoff K, Theurl I, Weiss G, Swinkels DW, Tjalsma H, Maggiorini M, Krayenbuhl P, Rau M, Wojtal K, Mullhaupt B, Fried M, Gassmann M, Lutz T, Geier A. Adaptation of iron transport and metabolism to acute high altitude hypoxia in mountaineers. Hepatology 58: 2153-2162, 2013.
8. Haase VH. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol 299: F1-F13, 2010.
9. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford: Oxford University Press, 2002.
10. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell 142: 24-38, 2010.
11. Hultgren HN, Lopez CE, Lundberg E, Miller J. Physiologic studies of pulmonary edema at high altitude. Circulation 29: 393-408, 1964.
12. Kleger GR, Bärtsch P, Vock P, Heilig B, Roberts LJ, Ballmer PE. Evidence against an increase in capillary permeability in subjects exposed to high altitude. J Appl Physiol 81: 1917-1923, 1996.
13. Maggiorini M, Brunner-La Rocca HP, Peth S, Fischler M, Böhm T, Bernheim A, Kiencke S, Bloch KE, Dehnert C, Naeije R, Lehmann T, Bärtsch P, Mairbäurl H. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema. Ann Intern Med 145: 497-506, 2006.
14. Maggiorini M, Melot C, Pierre S, Pfeiffer F, Greve I, Sartori C, Lepori M, Hauser M, Scherrer U, Naeije R. High-altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation 103: 2078-2083, 2001.
15. Mairbäurl H, Schobersberger W, Oelz O, Bärtsch P, Eckardt KU, Bauer C. Unchanged in-vivo P 50 at high altitude despite decreased red cell age and elevated 2,3-DPG. J Appl Physiol 68: 1186-1194, 1990.
16. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101: 2461-2463, 2003.
17. Nguyen NB, Callaghan KD, Ghio AJ, Haile DJ, Yang F. Hepcidin expression and iron transport in alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 291: L417-L425, 2006.
18. Piperno A, Galimberti S, Mariani R, Pelucchi S, Ravasi G, Lombardi C, Bilo G, Revera M, Giuliano A, Faini A, Mainini V, Westerman M, Ganz T, Valsecchi MG, Mancia G, Parati G. Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project. Blood 117: 2953-2959, 2011.
19. Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JSR, Wharton J, Wilkins MR. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 58: 300-309, 2011.
20. Robach P, Recalcati S, Girelli D, Gelfi C, Aachmann-Andersen NJ, Thomsen JJ, Norgaard AM, Alberghini A, Campostrini N, Castagna A, Vigano A, Santambrogio P, Kempf T, Wollert KC, Moutereau S, Lundby C, Cairo G. Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. Blood 113: 6707-6715, 2009.
21. Smith TG, Balanos GM, Croft QP, Talbot NP, Dorrington KL, Ratcliffe PJ, Robbins PA. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol 586: 5999-6005, 2008.
22. Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, Leedham DL, Liu C, Maxwell PH, McMullin MF, McNamara CJ, Percy MJ, Pugh CW, Ratcliffe PJ, Talbot NP, Treacy M, Robbins PA. Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med 3: e290, 2006.
23. Smith TG, Talbot NP, Privat C, Rivera-Ch M, Nickol AH, Ratcliffe PJ, Dorrington KL, Leon-Velarde F, Robbins PA. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. J Am Med A 302: 1444-1450, 2009.
24. Sonnweber T, Nachbaur D, Schroll A, Nairz M, Seifert M, Demetz E, Haschka D, Mitterstiller AM, Kleinsasser A, Burtscher M, Trubsbach S, Murphy AT, Wroblewski V, Witcher DR, Mleczko-Sanecka K, Vecchi C, Muckenthaler MU, Pietrangelo A, Theurl I, Weiss G. Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB. Gut 63: 1951-1959, 2014.
25. Stockmann C, Fandrey J. Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clin Exp Pharmacol Physiol 33: 968-979, 2006.
26. Swenson ER, Maggiorini M, Mongovin S, Gibbs JSR, Greve I, Mairbäurl H, Bärtsch P. Pathogenesis of high-altitude pulmonary edema: Inflammation is not an etiologic factor. J Am Med A 287: 2228-2235, 2002.
27. Talbot NP, Lakhal S, Smith TG, Privat C, Nickol AH, Rivera-Ch M, Leon-Velarde F, Dorrington KL, Mole DR, Robbins PA. Regulation of hepcidin expression at high altitude. Blood 119: 857-860, 2012.
28. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13: 1096-1101, 2007.
29. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, Lee YT, Goodnough JB, Harandi O, Ganz T, Paulson RF, Miller JL. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 114: 181-186, 2009.
30. Weir EK, Archer SL. The mechanism of acute hypoxic pulmonary vasoconstriction: The tale of two channels. FASEB J 9: 183-189, 1995.